Twenty Canadian Fellows Participate in the
Inaugural Program
TORONTO, Dec. 19,
2024 /CNW/ - Takeda Canada Inc. (Takeda) is proud to
sponsor the Inaugural MILESTONE Canada Advanced Inflammatory Bowel
Disease (IBD) Fellows Initiative. This program aims to standardize
training, organize networks, and implement Entrustable Professional
Activities (EPAs) for advanced IBD fellows in Canada.
"The MILESTONE Canada Advanced IBD Fellows Initiative will
enhance patient care and help improve outcomes in Canada," said Vatro Mateljic, General Manager,
Takeda. "This program reflects Takeda's commitment to advancing
education and training to improve the lives of Canadians living
with IBD."
The MILESTONE initiative, organized by Cleveland Clinic's
Digestive Disease Institute, is a comprehensive program designed to
educate advanced IBD fellows, providing them with the specialized
skills and knowledge necessary to deliver high-quality,
multidisciplinary, and equitable care to an increasingly diverse
patient population.
"By offering this specialized training, we are ensuring that IBD
fellows not only understand the complexities of the disease but
also know how to provide the best possible care for patients from
all walks of life," said Dr. Florian
Rieder, Vice Chair, Co-Section Director Inflammatory Bowel
Diseases, at the Cleveland Clinic Digestive Disease Institute.
"This program empowers them to become skilled, confident, and
compassionate providers."
Dr. Rieder, along with Drs. Benjamin
Cohen (Cleveland Clinic), Christina
Ha (Mayo Clinic Arizona) and Meena
Bewtra (Penn Medicine) serve as the MILESTONE USA Steering Committee members and were
instrumental in launching this innovative program in
2021.
Managed in collaboration with the MILESTONE Canada Steering
Committee, the program will integrate virtual clinical practice
roundtable discussions, focus groups, didactics, and team-based
learning sessions. These activities will help fellows develop new
skills, foster confidence in evidence-based care, and build a
professional network for future collaboration.
"Peer learning and mentorship are crucial for developing the
next generation of IBD specialists. By sharing our experiences and
insights, we are helping fellows navigate complex clinical
scenarios and build a solid foundation for their future careers,"
said Dr. Cynthia Seow, MILESTONE
Canada Steering Committee. "This program not only enhances their
skills but also fosters a supportive community of professionals
dedicated to advancing IBD care."
The MILESTONE Canada Steering Committee consists of some of
Canada's most esteemed
gastroenterologists and mentors. They include:
- Dr. Cynthia Seow, Professor of Medicine, Division
of Gastroenterology and Hepatology
- Departments of Medicine and Community Health Sciences,
University of Calgary
- Dr. Brian Feagan, Professor of Medicine,
Epidemiology & Biostatistics Western
University and Senior Scientific Director, Alimentiv
Inc.
- Dr. Brian Bressler,
Director, Advanced IBD Training Program, Clinical Associate
Professor of Medicine, Division of Gastroenterology, University of British Columbia and Staff Physician
at St. Paul's Hospital
(Vancouver, BC)
- Dr. Chris Ma,
Associate Professor of Medicine, Community Health Sciences,
Division of Gastroenterology & Hepatology, University of Calgary, Vice-president, Canadian
Inflammatory Bowel Disease Research Consortium (CIRC), and Senior
Medical Director, Alimentiv Inc.
- Dr. Robert Battat,
Gastroenterologist, Department of Gastroenterology, Centre
hospitalier de l'Université de Montréal, Director of Clinical
Excellence and Translational Research in IBD, and Associate
Professor, Department of Medicine, Université de Montréal
For more information about the MILESTONE Canada Advanced IBD
Fellows Initiative, please contact Carrie
Bristor, MILESTONE Program Manager, at bristoc2@ccf.org.
About Takeda Canada Inc.
Takeda Canada Inc. is the
Canadian organization of Takeda Pharmaceutical Company Limited
(TSE: 4502/NYSE: TAK). Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience,
and vaccines. Together with our partners, we aim to improve the
patient experience and advance a new frontier of treatment options
through our dynamic and diverse pipeline. As a leading
values-based, R&D-driven biopharmaceutical company
headquartered in Japan, we are
guided by our commitment to patients, our people and the planet.
Our employees in approximately 80 countries and regions are driven
by our purpose and are grounded in the values that have defined us
for more than two centuries. For more information, visit:
https://www.takeda.com/en-ca/.
SOURCE Takeda Canada Inc.
